Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label maintenance study of oral tofacitinib in pediatric ulcerative colitis
NL-OMON58903Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Pfizer. Started Jan 2023; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON58903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58903.